GSK’s patent on lapatinib ditosylate revoked by IPAB
8th August, 2013 - 9:36 am
Categories:
IP Practice in India
Pharma/Biotech Patent Litigations
0 Comments
GSK’s granted patent IN221171 (‘171) on lapatinib ditosylate (marketed as Tykerb), a tyrosine kinase inhibitor for treating breast cancer, was revoked by IPAB by its order of 27th July, 2013. A revocation application was filed by Fresenius Kabi Oncology Limited. The patent is revoked on ground of non-compliance with S.3d alone on basis of no … Continue reading GSK’s patent on lapatinib ditosylate revoked by IPAB
Read more »